Here’s what you should know:
1. The company’s total revenue increased 114 percent year over year.
2. Despite the revenue increases, Cologuard orders decreased 36 percent year-over-year in the last 16 days of March and 63 percent in the first 20 days of April. Both decreases were attributable to the COVID-19 pandemic.
3. Still screening revenue related to Cologuard rose 35 percent from the first quarter of 2019 to hit $219 million.
4. Despite COVID-19-related setbacks, April was the first month year-over-year declines in Cologuard test orders stabilized.
5. To combat future COVID-19-related losses, Exact has taken multiple measures including corporate pay cuts, a 2 percent permanent workforce reduction, a series of furloughs and securing a $24 million loan through the Coronavirus Aid, Relief and Economic Security Act, the Milwaukee Business Journal reports.
6. Exact said these measures will result in $400 million in cost savings in 2020.
More articles on surgery centers:
Life after ramp-up: How COVID-19 will change ASCs forever
3 ASC nurses join COVID-19 front lines in New York
4 hospitals, health systems opening ASCs
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
